04:09 AM EDT, 10/03/2025 (MT Newswires) -- Mesoblast (MESO) said late Thursday that the US Medicare & Medicaid Services has assigned a J-Code to graft-versus-host disease treatment Ryoncil.

The permanent J-Code, J3402, facilitates reimbursement and broader patient access for the drug, the drugmaker said.

Healthcare providers can start using the code for claims filed on or after Oct. 1, Mesoblast said.